Myfembree, a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, is approved for premenopausal women with heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with …
To characterize the experiences of individuals taking hormonal therapies to manage their symptoms of endometriosis (EM) or uterine fibroids (UF).
Background: Endometriosis affects approximately 6-10% of women of reproductive age-an estimate that varies substantially with the diagnostic standard applied-and is increasingly recognized as a systemic inflammatory disease. Growing evidence implicates …
To evaluate the effectiveness and tolerability of dienogest in patients with endometriosis in real-world clinical practice.
Rural, regional and remote (henceforth 'rural') communities face unique health challenges, including limited access to health care, workforce shortages, and higher disease burden. Consumer and community involvement is essential for …
Engineering education built for real-world impact Free Malaysia Today
Dienogest Evidence Comes With Real-World Tradeoffs streamlinefeed.co.ke
Endometriosis has limited treatment options, prompting the search for data-driven therapeutics. We previously used a transcriptomics-based computational drug repositioning pipeline and identified several drug candidates. Fenoprofen, our top in silico …
Endometriosis-associated infertility (EAI) has emerged as an increasingly pressing reproductive health problem. Nevertheless, existing epidemiological research on EAI remains inadequate.
Artificial intelligence (AI) has emerged as a transformative tool in radiological diagnosis, particularly in urogynaecology and obstetric disorders where accurate and timely imaging is essential. This narrative review evaluates current …